Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Cash Flow (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Net Cash Flow for 7 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 42.15% to $13.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$23.5 million through Dec 2025, down 196.46% year-over-year, with the annual reading at -$23.5 million for FY2025, 196.46% down from the prior year.
  • Net Cash Flow hit $13.9 million in Q4 2025 for Allogene Therapeutics, up from -$14.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $119.6 million in Q2 2024 to a low of -$119.4 million in Q3 2024.
  • Historically, Net Cash Flow has averaged -$6.5 million across 5 years, with a median of -$12.9 million in 2021.
  • Biggest YoY gain for Net Cash Flow was 288.89% in 2023; the steepest drop was 294.36% in 2023.
  • Year by year, Net Cash Flow stood at -$15.9 million in 2021, then grew by 21.5% to -$12.5 million in 2022, then surged by 211.69% to $13.9 million in 2023, then soared by 72.4% to $24.0 million in 2024, then tumbled by 42.15% to $13.9 million in 2025.
  • Business Quant data shows Net Cash Flow for ALLO at $13.9 million in Q4 2025, -$14.5 million in Q3 2025, and $9.9 million in Q2 2025.